The University of Kentucky has been selected as a testing site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase III clinical research study ENSEMBLE 2, which is evaluating the safety and efficacy of a two-dose regimen of Janssen’s COVID-19 vaccine candidate.
The Phase III ENSEMBLE 2 study is a randomised, double-blind, placebo-controlled clinical trial in up to 30,000 adults 18 years old and older. The trial will include people both with and without comorbidities associated with an increased risk for severe COVID-19.
The university was the top enrolling site in the world for the ongoing Phase III ENSEMBLE study, which evaluated a single-dose regimen of Janssen’s investigational vaccine. Recently released interim results of that global trial showed that a single dose of their vaccine candidate completely prevented hospitalisation and death from COVID-19 and was 85% effective in preventing severe illness — even against the South Africa variant. The investigational vaccine was 72% effective in the US for preventing moderate to severe illness.
The two-dose ENSEMBLE 2 study is running in parallel to and separate from that ongoing Phase III ENSEMBLE single-dose trial, which enrolled more than 43,000 participants across three continents. Conducting the ENSEMBLE and ENSEMBLE 2 trials in parallel will provide valuable insights into the dosing schedules and help determine a path forward in both the short term and the long term to potentially help end the fast-moving COVID-19 pandemic.
UK will enroll up to 200 adults, 18 years and older from the Lexington area in the ENSEMBLE 2 trial. Nearly 900 local volunteers are participating in the single-dose ENSEMBLE trial. Participants in both trials will be monitored for up to two years to ensure robust safety and efficacy data.
The Janssen COVID-19 vaccine candidate leverages the company’s AdVac technology platform, which was also used to develop and manufacture Janssen’s European Commission-approved Ebola vaccine and construct its Zika, RSV, and HIV investigational vaccine candidates. Janssen’s AdVac technology platform has been used to vaccinate more than 200,000 people to date across the company’s investigational vaccine programs.
At the forefront of UK’s COVID-19 vaccine clinical trials is Dr. Richard Greenberg, who has more than 40 years’ experience in vaccine development studies, including working with the World Health Organization, the Department of Defense, and the VA.
“Our team is honoured to continue working in this historic effort to end this pandemic and save lives. We are grateful to all the local volunteers who enrolled in ENSEMBLE 1 and who will join us in ENSEMBLE 2. The only way for us to overcome this global crisis is to work together,” Greenberg said. “With the encouraging interim results of Janssen’s single-dose regimen, we’re excited to be part of this two-dose trial that will ensure the most effective dosing schedule.”
The UK Center for Clinical and Translational Science (CCTS) is implementing the ENSEMBLE and ENSEMBLE 2 trials at UK, and serves as the organizing centre for the ENSEMBLE 1 tri-hospital site that UK led with Baptist Health Lexington and Norton Healthcare in Louisville.
“Providing the engine for the ENSEMBLE trials at UK epitomizes our mission of accelerating discoveries to improve health,” said Dr. Philip Kern, director of the CCTS.